


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+11.78%
-6.36%
+3.34%
+6.85%
GPCR
Structure Therapeutics In
$88.45
Strengths

Upgraded on attractively valued

Outperform the market
GPCR Price Performance
$62.77 (+40.91%)
$32.27 (+174.09%)
$21.25 (+316.24%)
$19 (+365.53%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Outperform the market
![]()
GPCR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
GPCR Street Sentiment is extremely bullish and have positive views on the near-term outlook
GPCR has Low risk level
Risks Indicators

High volatilty

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Jan 06, 2026
Reiterate
Overweight
Cantor Fitzgerald
Dec 13, 2025
Reiterate
Outperform
Citizens
Dec 13, 2025
Reiterate
Overweight
Morgan Stanley
Dec 12, 2025
Reiterate
Buy
Jefferies
Dec 10, 2025
Reiterate
Buy
Citigroup
VKTX
Viking Therapeutics
29.04
-3.97%
PFE
Pfizer
26.44
+1.34%
NVO
Novo Nordisk A/S
59.43
+0.17%
LLY
Eli Lilly and
1037.15
+1.31%
GPCR
Structure Therapeutics In
88.45
+1.49%
OKTA
Okta
84.43
-1.41%
RBRK
Rubrik Inc.
55.95
-3.47%
NET
Cloudflare
177.35
-1.72%
BCX
BlackRock Resources
12.47
-2.81%
What is GPCR current stock price?
What are GPCR stock strengths?
What is GPCR Risk Level?
What is GPCR market cap and volume?
What is GPCR current Stock IQ?
Should I buy GPCR stock right now?
Is GPCR a Strong Buy right now?
What does a 'Strong Buy' rating mean for GPCR?
What does a 'Strong Sell' rating mean for GPCR?
What factors influence GPCR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+11.78%
-6.36%
+3.34%
+6.85%
GPCR
Structure Therapeutics In
Current Price
$88.45
Linked to GPCR
VKTX
Viking Therapeutics
29.04
-3.97%
PFE
Pfizer
26.44
+1.34%
NVO
Novo Nordisk A/S
59.43
+0.17%
LLY
Eli Lilly and
1037.15
+1.31%
Recently Viewed
GPCR
Structure Therapeutics In
88.45
+1.49%
OKTA
Okta
84.43
-1.41%
RBRK
Rubrik Inc.
55.95
-3.47%
NET
Cloudflare
177.35
-1.72%
BCX
BlackRock Resources
12.47
-2.81%

GPCR Price Performance
$62.77 (+40.91%)
$32.27 (+174.09%)
$21.25 (+316.24%)
$19 (+365.53%)
GPCR Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Outperform the market
![]()
GPCR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
GPCR Street Sentiment is extremely bullish and have positive views on the near-term outlook
GPCR has Low risk level
Risks Indicators

High volatilty

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 06, 2026
Reiterate
Overweight
Cantor Fitzgerald
Dec 13, 2025
Reiterate
Outperform
Citizens
Dec 13, 2025
Reiterate
Overweight
Morgan Stanley
Dec 12, 2025
Reiterate
Buy
Jefferies
Dec 10, 2025
Reiterate
Buy
Citigroup
Dec 10, 2025
Reiterate
Buy
Clear Street
Dec 10, 2025
Reiterate
Buy
Stifel
GPCR Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Outperform the market
GPCR Latest Analysis
Structure Therapeutics gains on report suggesting it may be a top takeover target.
Fri Jan 30, 2026
Jim Cramer on Structure Therapeutics: I Dont Want to Touch It. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramers radar recently. When a caller inquired about the stock Cramer commented: Oh okay so this is a they have a deal with Roche and therefore I think its a legitimate idea but boy the stock fully reflects that deal. I dont want to [….]
Fri Jan 16, 2026
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why. Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The companys shares have gained over 130% in the past three months with a major surge since early December after reporting positive data related to its oral obesity pill. A study testing aleniglipron on obese or overweight patients with one [….]
Thu Jan 15, 2026
Structure Therapeutics Inc. - Depositary Receipt (GPCR) Price Target Increased by 10.08% to 103.82. The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to $103.82 / share. This is an increase of 10.08% from the prior estimate of $94.31 dated December 18 2025. The price target is an average
Wed Jan 14, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GPCR Stock trends
GPCR Stock performance
GPCR Stock analysis
GPCR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.